KANSAS CITY, KAN. The Kansas University Medical Center will be one of 270 sites in the United States and Canada to participate in the first large-scale breast cancer prevention study for women at increased risk for the disease, according to a recent release from the medical center.
Sponsored by the U.S. National Cancer Institute, and conducted by the National Surgical Adjuvant Breast and Bowel Project, the study will determine whether tamoxifen, an anti-estrogen drug, is effective in preventing breast cancer.
The study also will evaluate whether tamoxifen lowers the number of deaths from heart attacks and reduces the number of bone fractures in women who receive the drug.
Dr. Carol Fabian, professor of medicine and medical director of the KU Cancer Center, will be the principal investigator, and Dr. Richard McKittrick, assistant professor of medicine, will be the co-investigator and project coordinator.
Across the nation, the study will involve 16,000 women, age 35 and older, who are considered at increased risk for breast cancer. Half the women will receive tamoxifen and half will receive a placebo for five years.
Women who are interested in participating in the study may call KUMC at 1-588-4092.